Share on StockTwits

Northwest Biotherapeutics (NASDAQ:NWBO) posted its quarterly earnings results on Wednesday. The company reported ($0.46) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.33) by $0.13, Analyst Ratings reports.

Shares of Northwest Biotherapeutics (NASDAQ:NWBO) opened at 5.74 on Wednesday. Northwest Biotherapeutics has a 52 week low of $3.10 and a 52 week high of $10.64. The stock has a 50-day moving average of $6.12 and a 200-day moving average of $5.45. The company’s market cap is $328.3 million.

NWBO has been the subject of a number of recent research reports. Analysts at Oppenheimer downgraded shares of Northwest Biotherapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, March 12th. They now have a $5.00 price target on the stock. They noted that the move was a valuation call. Analysts at Summer Street raised their price target on shares of Northwest Biotherapeutics from $10.33 to $15.10 in a research note on Tuesday, March 11th. They now have a “buy” rating on the stock.

Northwest Biotherapeutics, Inc is a development-stage company. The Company focuses on discovering, developing, and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.